Alpha Sense BI

AUGUST 30, 2023

Research shows that the AI in asset management market will grow at a staggering 34% CAGR through 2027. The time is now to invest in a market intelligence platform with AI search capabilities, so you can speed up your research and outperform the market.

Management 98

Management Biotech Due Diligence Algorithm 98

Alpha Sense BI

MAY 5, 2023

M&A Trends by Industry Healthcare The COVID-19 pandemic ushered in a wave of unprecedented innovation, progress, and transformation to the healthcare industry in 2020. Many pharma companies with expiring patents are on the hunt to acquire biotech companies to address gaps in drug pipelines. Start your free trial today.

Biotech 97

Biotech Capital Banking Startups 97

Alpha Sense BI

APRIL 29, 2024

This staggering statistic is representative of a transformative shift in the asset management space away from archaic research methods. Generative AI in venture capital streamlines workflows, reduces research and due diligence blind spots, and surfaces qualitative and quantitative insights to make data-driven decisions faster.

Capital 52

Capital Due Diligence Biotech Startups 52

Alpha Sense BI

APRIL 19, 2024

2020 and 2021 were marked by increased innovation, accelerated growth, and workforce expansion. Inflationary pressures are forecasted to ease and new innovations are capturing the attention of consumers, investors, and executives across various industries. As we navigate 2024, the landscape appears positioned for a triumphant comeback.

Technology 69

Technology Technology Retail Biotech 69

Engage3

MAY 19, 2022

Ken served on the Board of Directors of Revionics between 2007-2011 and as Chief Scientist & VP of Innovations at SAP AG between 2006-2007. Tim Ouimet Founder & Board Observer Tim Ouimet is a Founder and Board Member at Engage3 and is a recognized industry innovator in retail pricing strategies.

Retail 52

Retail Capital Finance Biotech 52

Alpha Sense BI

MARCH 13, 2024

According to an outlook published by PwC , “large-cap pharma companies are expected to continue pursuing mid-sized biotech companies to fill pipeline gaps in the face of impending patent cliffs. In January, HATCo announced its intent to acquire Summa Health of Ohio , a non-profit healthcare system, with a focus to “put innovation in.”

Pharmaceutical 59

Pharmaceutical Hospitals Due Diligence Biotech 59